At a market cap of 4.7B EUR and EV/EBITDA of 4.8, Arkema is attractively priced, even with a potential 15% EBITDA reduction.

Mastercard is definitely a wonderful business, both when assessed qualitatively and quantitatively. The future risks for the ...

When markets move, we can learn a lot from the outperformers. But we can also learn a lot from the underperformers - and ...

Adriatic Metals PLC upgraded to Buy due to Vareš project ramp-up, expected commercial production in Q1 2025, and favorable ...

KREF's Series A is attractively priced for a company with a credit rating of B+. Though current yields of near 9% exist, ...

Rocket Lab's heavy reliance on government contracts makes it especially vulnerable to cost-cutting in this sector. Check out ...

VitalHub, a healthcare software provider, has seen an 18% drop since January 2025 despite a 30% revenue growth during FY2024.

Fidelity National Information Services, Inc. and Global Payments Inc. reshuffle positions with $37.75B deals. Click for ...

By Diederik StadigUS President Donald Trump signed a new executive order on 15 April aimed at bringing US drug prices down.

We are presenting at the Santangel’s Roundtable in New York City on Wednesday 7th May 2025 and look forward to meeting to ...

OPTZ, a unique all-cap ETF with GARP features. Low 14.77x P/E and high-growth potential, but higher risk. See more on OPTZ ...

Rising medical costs impacted UnitedHealth's earnings and market cap. Read about UNH's long-term growth potential despite its ...